Close Menu

NEW YORK – Integrated analysis of tumor and normal samples from cancer patients combined with RNA profiling of their tumor helps match those patients to targeted therapies and clinical trials, according to a new study from Tempus Labs.

In their paper, appearing today in Nature Biotechnology, Tempus researchers applied their approach to 500 patient samples representing a range of tumor types.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.